PediaMed Ventures · Last-Mile Investment

Capital for the last mile.

Advancing pediatric therapies that are both clinically meaningful and commercially viable — validated medicines that stall before reaching children, and the expertise to finish them.

Investment Thesis

Two conditions. No compromise on either.

We invest where the science is largely settled but execution has stalled — pediatric medicines that are both clinically meaningful and commercially viable, refusing to treat the two as a trade-off.

  • 01Clinically meaningful — therapies that change the course of a child's care, not the margins of it.
  • 02Commercially viable — durable economics that let impact compound and sustain itself.

Outcome — drives approval, adoption, and sustainable scale.

Focus Areas

Where overlooked value meets pediatric need.

01

Phase 3 & post-approval assets

Late-stage and approved therapies where the science is resolved but momentum has stalled.

02

Adult-to-pediatric expansion

Established therapies never advanced into the pediatric indications children need.

03

Underutilized approved therapies

Pediatric-labeled medicines that exist but never reach the children who need them.

04

Shelved programs

Assets parked after portfolio shifts — with a clear path forward.

Platform Advantage

More than capital.

PediaMed combines investment discipline with deep commercialization expertise — helping portfolio companies accelerate growth and patient access alike.

Most investors stop at the check. We bring the operating capability to turn a promising pediatric asset into a therapy children can actually reach — the same expertise that built the platform behind us.

Governance

Independent by design.

Independent governance

Ventures operates under its own governance and investment discipline.

Separate from the Institute

Investment capital and philanthropic capital never commingle.

Mission aligned

Two paths, one mission — distinct mandates, shared purpose for children.

Request Information

For LPs, family offices, and strategic partners.

The Other Engine

Some medicines serve children the market will never reward. Those have a path too.

Explore the PediaMed Institute